Lobe Sciences Ltd.
Lobe Sciences Ltd.

The Company is working to develop psychedelic compounds as therapeutics. Initially the Company will develop psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of these medications. The Company also owned acquired brands, intellectual property and leases office and production premises to a cannabis processor and retailer which were disposed of on March 5, 2021.
Lobe Sciences Ltd. (LOBE)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Bulletins
2022-0613 – Consolidation - Lobe Sciences Ltd. (LOBE)
le 9 juin/June 2022
Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.
As a result, the outstanding common shares of the Issuer will be reduced to approximately 38,230,000 common shares.
Advertisement
Publicité